Edwards Lifesciences Corporation (EW) fair value analysis

S&P 500 · Updated 2026-09-07

Edwards Lifesciences Corporation manufactures and distributes medical devices and therapies focused on structural heart disease, critical care monitoring, and surgical applications. The company operates globally across North America, Europe, Asia Pacific, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, EW is trading at a 10–25% discount to estimated fair value.

EW currently ranks #50 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $89.90
Sector: Healthcare
12-month range: $81.26–$90.74

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range

What our data shows for EW

Our model validated 17 trailing price-to-earnings windows for EW, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $81.26–$90.74.
The 14-day relative strength index sits at a neutral 51.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for EW
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent EW news

TickrTrends' derived news-sentiment signal for EW is currently leaning positive, computed from recent coverage.

Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) (seekingalpha.com, 2026-09-07)
TickrTrends take: Edwards Lifesciences operates in a substantial market opportunity, with analysts identifying a 20 billion dollar total addressable market that could support long-term growth. Given TickrTrends' current undervalued assessment, investors focused on valuation metrics should monitor whether the company can successfully execute within this large market segment to justify its current pricing. The Healthcare sector's growth dynamics and EW's competitive positioning within its addressable market remain key factors for evaluating whether the undervalued status reflects genuine opportunity or unpriced execution risks.
Edwards Lifesciences (EW) Announces Retirement of Corporate Vice President Donald E. Bobo Jr. (gurufocus.com, 2026-08-29)
TickrTrends take: Edwards Lifesciences' announcement of a corporate vice president retirement represents a routine management transition within the healthcare sector company. Given TickrTrends' current undervalued assessment, investors focused on valuation metrics should monitor whether this leadership change affects the company's operational efficiency or capital allocation strategies that underpin the undervaluation thesis. Management continuity and execution capability are factors that can either support or challenge a stock's valuation positioning.
Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom (finance.yahoo.com, 2026-08-28)
TickrTrends take: Edwards Lifesciences maintains a position as a significant player in the transcatheter aortic valve replacement market, a sector experiencing sustained demand growth. Given TickrTrends' undervalued assessment, investors monitoring Healthcare valuations may want to track whether the company's TAVR-focused business model continues to justify its current market price relative to growth and profitability metrics. The dominance in this specialized medical device category represents a key factor in evaluating whether the valuation gap persists or narrows over time.

What people are saying

Follow the EW conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is EW stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), EW is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is EW's TickrTrends verdict?

EW's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does EW compare to other Healthcare stocks?

EW ranks #50 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is EW overbought or oversold?

EW's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

EW vs BDX · EW vs BTSG · EW vs EXEL · EW vs GMAB · EW vs HCA